Form 4: BioLife Solutions Chief Marketing Officer Sells Shares Under 10b5-1 Plan

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 91 shares of common stock at $26.34 per share on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Todd Berard, the Chief Marketing Officer of BioLife Solutions, sold 91 shares of the company's common stock on November 12, 2024.
• The sale was executed at a price of $26.34 per share.
• This transaction was conducted under a pre-existing Rule 10b5-1 trading plan adopted by Mr. Berard on February 8, 2021.
• The purpose of the sale was to cover tax withholding obligations related to the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-existing plan, with no indication of positive or negative sentiment. It is a neutral event.

Risks

• Sales by company insiders can sometimes be perceived negatively by the market, although this sale was pre-planned.

Industry Context

This is a routine transaction for executives who use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading. It is common for executives to sell shares to cover tax obligations.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without the appearance of trading on non-public information.
• Many executives at comparable companies such as Thermo Fisher Scientific and Danaher Corporation also utilize 10b5-1 plans for similar purposes.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders, as it was a small transaction under a pre-arranged plan.

Key Dates

Keywords

BioLife Solutions, BLFS, insider trading, Todd Berard, Rule 10b5-1, stock sale, Chief Marketing Officer, equity securities